cas 53857-57-1|| where to buy 5-bromo-1H-indazole

Nombre del producto:5-bromo-1H-indazole

IUPAC Name:5-bromo-1H-indazole

Unidad de embalaje	Stock disponible	Precio($)
CM100735-100g	in stock	ǎř
CM100735-500g	in stock	Əǭř

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 53857-57-1 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :53857-57-1; Fórmula molecular:C7H5BrN2; Punto de fusión:-; Código de sonrisas:BrC1=CC2=C(NN=C2)C=C1; Densidad:1.77 g/cm3

: Número de catálogo:CM100735; Peso molecular:197.04; Punto de ebullición:333.8°C at 760 mmHg; Nº Mdl:MFCD00839493; Almacenamiento:Pretect from light and store in a dry and close container at room temperature

: Indazoles; Indazoles are a class of organic heterocyclic compounds, also known as 1,2-diazaindene and benzopyrazole. Indazole is a good bioisomer of phenol, which is more lipophilic than phenol and less prone to phase I and II metabolism. Indazole derivatives have a wide range of biological activities, and it has been confirmed that indazole compounds have anti-tumor, analgesic, anti-inflammatory and other drug activities. Anticancer is the most important application field of indazole drugs. Renal cell carcinoma, solid tumor, nausea and vomiting caused by chemotherapy and leukemia are the main indications of this structural backbone drug.

: Orforglipron; Obesity is becoming an increasingly serious public health problem globally, plaguing millions of people and significantly increasing their risk of chronic diseases such as diabetes and heart disease. In recent years, with the approval of new weight loss drugs such as Wegovy (Semaglutide) and Mounjaro (Tirzepatide), people's attention to this field has once again heated up, spawning an upsurge in the research and development of new treatments. There are currently nearly 70 obesity treatments in the research and development stage. Eli Lilly's Orforglipron is the world's first oral small molecule GLP-1RA to start Phase III clinical trials.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.